• SENSEX
    NIFTY 50
Ekta Batra

Ekta Batra

Anchor & Associate Editor Research

@ekta_batra

Ekta Batra has been with CNBC-TV18 since October 2008. Ekta anchors daily prime time market shows such as 'Trading Hour', 'Power Breakfast' and 'Your Stocks'. Ekta has also been tracking the Indian Pharma & Healthcare landscape now for almost a decade. She also looks at macro-economics and has previously tracked the financial sector.

Ekta holds a Masters Degree in Business Management from University of Warwick, England and a Bachelors Degree (with Honors) in Business and Communication from Ithaca College, New York. Prior to working with CNBC-TV18, Ekta has worked on projects with McKinsey & Company and Bank of America Merrill Lynch as an Investment Associate.

Articles by Ekta Batra

MarketBuzz Podcast With Ekta Batra: Sensex, Nifty likely to open flat; Infosys, Bharti Airtel in focus
Market 09 Apr 08:36 AM IST

MarketBuzz Podcast With Ekta Batra: Sensex, Nifty likely to open flat; Infosys, Bharti Airtel in focus

  • The Indian market is likely to open flat with a negative bias Friday as the trend on SGX Nifty indicates a subdued start for the broader index in India. The Nifty futures were trading 36.50 points or 0.24 percent lower at the 14,909.50 level on the Singaporean Exchange at 8:25 am.
Market 08 Apr 08:27 AM IST

MarketBuzz Podcast With Ekta Batra: Sensex, Nifty likely to open higher; Bharti Airtel, Vedantain focus

The Indian market is likely to open higher Thursday as the trend on SGX Nifty indicates a positive start for the broader index in India. The Nifty futures were trading 53.00 points or 0.36 percent higher at the 14,916.50 level on the Singaporean Exchange at 8:15 am.

Business 05 Mar 11:55 PM IST

Kiska Brand Bajega: Here's the success story of Spotify India

India 26 Feb 12:59 PM IST

Government gives nod to 11 bulk drug cos under PLI scheme

Market 21 Dec 07:35 PM IST

Recap 2020: Pharma index had a dream year, thanks to COVID-19

Market 01 Jun 01:10 PM IST

Biocon partner Mylan gets favorable ruling in patent case on Insulin Glargine

Advertisement